AZALEA: A Phase II study of atezolizumab, vinorelbine and weekly cyclophosphamide as T-cell activators in first line metastatic triple negative breast cancer patients pre-treated with anti-PD-L1/PD-1

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514031-20-00

Enrollment

Registered

2024-08-07

Start date

2025-02-24

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

Brief summary

overall response rate

Detailed description

Duration of response (DOR), Progression-free survival (PFS), Overall survival (OS), Safety of the combination regimen

Interventions

DRUGTecentriq 840 mg concentrate for solution for infusion

DRUGVINORELBINE

DRUGCYCLOPHOSPHAMIDE MONOHYDRATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
overall response rate	—

Secondary

Measure	Time frame
Duration of response (DOR), Progression-free survival (PFS), Overall survival (OS), Safety of the combination regimen	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026